ariadne.ai secures funding to revolutionize the treatment of glioblastoma

ariadne.ai (Germany) GmbH has announced that it has been awarded €518,000 in non-dilutive funding from the State of Baden-Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of glioblastoma by creating a digital twin with unprecedented biological fidelity.

Digital twins, virtual models that simulate tumor behavior, hold the promise of accelerating drug discovery and personalizing patient care. However, their predictive power is strictly limited by the quality and depth of the data on which they are trained. Current models often fail to capture the complex interplay between tumor cells and the surrounding neural tissue.

TumorTwin utilizes the capabilities of SPATIAL™, the company’s flagship platform designed for the analysis of 3D spatial multi-omics data. SPATIAL™ can perform morphometric spatial multi-omics analysis on brain data, putting ariadne.ai in a unique position to solve this challenge.

“We just returned from SfN (Society for Neuroscience) in November and saw the incredible momentum spatial biology technologies have gained in neuroscience," said Lucas Schuetz, Chief Commercial Officer at ariadne.ai. "Our SPATIAL™ platform is already being used across different disease areas by premier institutions like Stanford, Columbia University, Houston Methodist, and OHSU. It is time to make use of this established capability to tackle the complexities of glioblastoma and provide the market with a tool that truly understands the neural-tumor interface."

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>